| CAS ID: | 1258226-87-7 |
| Molecular Formula: | C50H67N7O8 |
| Molecular Weight: | 894.1 g/mol |
| Monoisotopic Mass: | 893.5051 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | OMBITASVIR | ABT-267 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1 | See All |
| InChI Key: | PIDFDZJZLOTZTM-KHVQSSSXSA-N | |
| Smiles: | COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)cc5 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT02442284 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 13, 2015 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 2
| ClinicalTrial ID | NCT02806362 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Withdrawn |
| First Received | June 20, 2016 | Last Verified | December 5, 2016 |
| Sponsor | AbbVie | ||
Trial Record 3
| ClinicalTrial ID | NCT02265237 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 15, 2014 | Last Verified | August 31, 2017 |
| Sponsor | AbbVie | ||
Trial Record 4
| ClinicalTrial ID | NCT02219477 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | July 11, 2017 |
| Sponsor | AbbVie | ||
Trial Record 5
| ClinicalTrial ID | NCT02207088 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 1, 2014 | Last Verified | November 9, 2017 |
| Sponsor | AbbVie | ||
Trial Record 6
| ClinicalTrial ID | NCT01995071 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 26, 2013 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 7
| ClinicalTrial ID | NCT02517528 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 7, 2015 | Last Verified | October 8, 2018 |
| Sponsor | AbbVie | ||
Trial Record 8
| ClinicalTrial ID | NCT01704755 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 11, 2012 | Last Verified | October 19, 2015 |
| Sponsor | AbbVie (prior sponsor, Abbott) | ||
Trial Record 9
| ClinicalTrial ID | NCT02219503 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | June 29, 2016 |
| Sponsor | AbbVie | ||
Trial Record 10
| ClinicalTrial ID | NCT01939197 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | September 11, 2013 | Last Verified | November 17, 2017 |
| Sponsor | AbbVie | ||
Trial Record 11
| ClinicalTrial ID | NCT03053180 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | February 15, 2017 | Last Verified | March 14, 2019 |
| Sponsor | AbbVie | ||
Trial Record 12
| ClinicalTrial ID | NCT02640547 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | December 29, 2015 | Last Verified | October 17, 2018 |
| Sponsor | AbbVie | ||
Trial Record 13
| ClinicalTrial ID | NCT02636608 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | December 22, 2015 | Last Verified | May 30, 2018 |
| Sponsor | AbbVie | ||
Trial Record 14
| ClinicalTrial ID | NCT02615145 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | November 26, 2015 | Last Verified | April 12, 2018 |
| Sponsor | AbbVie | ||
| PubChem: | 54767916 |
| ChEMBL: | CHEMBL3127326 |